Castle Biosciences COO Kristen Oelschlager Sells Shares

What Happened
Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), sold a total of 8,586 shares in open‑market transactions on August 3, 2026 for aggregate proceeds of about $255,622. The sales were: 3,000 shares at $29.12 ($87,360); 4,486 shares at a weighted‑average price of $30.00 ($134,580); and 1,100 shares at $30.62 ($33,682). These were dispositions (sales), which are often routine liquidity events rather than statements about company prospects.

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (timely — within the required reporting window).
• Individual transactions and reported weighted‑average prices: 3,000 @ $29.12; 4,486 @ $30.00; 1,100 @ $30.62. Total proceeds ≈ $255,622.
• Footnote F1: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted March 17, 2026.
• Footnotes F2–F4: Each reported price is a weighted average; the transactions were executed in multiple trades at price ranges of $28.46–$29.45, $29.53–$30.44, and $30.55–$30.71 respectively. The reporting person will provide detailed trade-level prices upon request.
• Footnote F5: Some holdings are held by the Fritz Shorter Trust, of which the reporting person and spouse are trustees and beneficiaries.
• Shares owned after the transactions: not specified in the information provided.

Context
These sales were executed under a pre‑arranged Rule 10b5‑1 plan, which allows insiders to sell shares according to a set schedule and is commonly used to avoid timing concerns. Sales do not necessarily indicate negative views about the company; retail investors should consider these transactions alongside company fundamentals and other insider activity.